Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response.
Antibodies, Neutralizing
/ genetics
Antibodies, Viral
/ genetics
Epitopes
/ immunology
Humans
Immunoglobulin A
/ immunology
Immunoglobulin G
/ immunology
Immunoglobulin M
/ immunology
Proteins
/ immunology
Respiratory Syncytial Virus Infections
/ immunology
Respiratory Syncytial Virus Vaccines
Respiratory Syncytial Virus, Human
/ genetics
Viral Fusion Proteins
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 02 2021
11 02 2021
Historique:
received:
21
04
2020
accepted:
20
11
2020
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Human respiratory syncytial virus (RSV) is one of the most important causes of severe respiratory tract infections in early childhood. The only prophylactic protection is the neutralizing antibody, palivizumab, which targets a conformational epitope of the RSV fusion (F) protein. The F protein is generated as a F0 precursor containing two furin cleavage sites allowing excision of the P27 fragment and then gives rise to a fusion-competent version consisting of the N-terminal F2 subunit and the a C-terminal F1 subunits linked by two disulphide bonds. To investigate natural human F-specific antibody responses, F2 conferring the species-specificity of RSV, was expressed in Escherichia coli. Furthermore, the F0 protein, comprising both subunits F2 and F1, was expressed as palivizumab-reactive glycoprotein in baculovirus-infected insect cells. Six overlapping F2-derived peptides lacking secondary structure were synthesized. The analysis of IgG, IgA and IgM responses of adult subjects to native versions and denatured forms of F2 and F0 and to unfolded F2-derived peptides revealed that mainly non-conformational F epitopes, some of which represented cryptic epitopes which are not exposed on the proteins were recognized. Furthermore, we found a dissociation of IgG, IgA and IgM antibody responses to F epitopes with F2 being a major target for the F-specific IgM response. The scattered and dissociated immune response to F may explain why the natural RSV-specific antibody response is only partially protective underlining the need for vaccines focusing human antibody responses towards neutralizing RSV epitopes.
Identifiants
pubmed: 33574352
doi: 10.1038/s41598-021-82893-y
pii: 10.1038/s41598-021-82893-y
pmc: PMC7878790
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Epitopes
0
F protein, human
0
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Proteins
0
Respiratory Syncytial Virus Vaccines
0
Viral Fusion Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3551Subventions
Organisme : Austrian Science Fund FWF
ID : P 29398
Pays : Austria
Références
Nair, H. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 375, 1545–1555 (2010).
pubmed: 20399493
pmcid: 2864404
doi: 10.1016/S0140-6736(10)60206-1
Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128 (2012).
pubmed: 23245604
doi: 10.1016/S0140-6736(12)61728-0
Jartti, T. et al. Bronchiolitis needs a revisit: Distinguishing between virus entities and their treatments. Allergy Eur. J. Allergy Clin. Immunol. 74, 40–52 (2019).
doi: 10.1111/all.13624
Hall, C. B., Long, C. E. & Schnabel, K. C. Respiratory syncytial virus infections in previously healthy working adults. Clin. Infect. Dis. 33, 792–796 (2001).
pubmed: 11512084
doi: 10.1086/322657
Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C. & Walsh, E. E. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352, 1749–1759 (2005).
pubmed: 15858184
doi: 10.1056/NEJMoa043951
Agius, G. et al. An epidemic of respiratory syncytial virus in elderly people: Clinical and serological findings. J. Med. Virol. 30, 117–127 (1990).
pubmed: 2179469
doi: 10.1002/jmv.1890300208
Volling, C. et al. Respiratory syncytial virus infection-associated hospitalization in adults: A retrospective cohort study. BMC Infect. Dis. 14, 665 (2014).
Hansel, T. T., Johnston, S. L. & Openshaw, P. J. Microbes and mucosal immune responses in asthma. Lancet 381, 861–873 (2013).
pubmed: 23428115
doi: 10.1016/S0140-6736(12)62202-8
Rima, B. et al. ICTV virus taxonomy profile: Pneumoviridae. J. Gen. Virol. 98, 2912–2913 (2017).
pubmed: 29087278
pmcid: 5775899
doi: 10.1099/jgv.0.000959
Morris, J. A., Blount, R. E. & Savage, R. E. Recovery of cytopathogenic agent from chimpanzees with goryza. Proc. Soc. Exp. Biol. Med. 92, 544–549 (1956).
pubmed: 13359460
doi: 10.3181/00379727-92-22538
Chanock, R., Roizman, B. & Myers, R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA): Isolation, properties and characterization. Am. J. Epidemiol. 66, 281–290 (1957).
doi: 10.1093/oxfordjournals.aje.a119901
Chanock, R. & Finberg, L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA): Epidemiologic aspects of infection in infants and young children. Am. J. Epidemiol. 66, 291–300 (1957).
doi: 10.1093/oxfordjournals.aje.a119902
Johnson, P. R. et al. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J. Virol. 61, 3163–3166 (1987).
pubmed: 3305988
pmcid: 255893
doi: 10.1128/jvi.61.10.3163-3166.1987
Sullender, W. M. Respiratory syncytial virus genetic and antigenic diversity. Clin. Microbiol. Rev. 13, 1–15 (2000).
pubmed: 10627488
pmcid: 88930
doi: 10.1128/CMR.13.1.1
Peret, T. C. T., Hall, C. B., Schnabel, K. C., Golub, J. A. & Anderson, L. J. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J. Gen. Virol. 79, 2221–2229 (1998).
pubmed: 9747732
doi: 10.1099/0022-1317-79-9-2221
Walsh, E. E., McConnochie, K. M., Long, C. E. & Hall, C. B. Severity of respiratory syncytial virus infection is related to virus strain. J. Infect. Dis. 175, 814–820 (1997).
pubmed: 9086135
doi: 10.1086/513976
Obando-Pacheco, P. et al. Respiratory syncytial virus seasonality: A global overview. J. Infect. Dis. 217, 1356–1364 (2018).
pubmed: 29390105
doi: 10.1093/infdis/jiy056
Simões, E. A. F. et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect. Diseases Therapy 7, 87–120 (2018).
doi: 10.1007/s40121-018-0188-z
Papadopoulos, N. G. et al. Promising approaches for the treatment and prevention of viral respiratory illnesses. J. Allergy Clin. Immunol. 140, 921–932 (2017).
pubmed: 28739285
pmcid: 7112313
doi: 10.1016/j.jaci.2017.07.001
Khaitov, M. R. et al. Small interfering RNAs targeted to interleukin-4 and respiratory syncytial virus reduce airway inflammation in a mouse model of virus-induced asthma exacerbation. Hum. Gene Ther. 25, 642–650 (2014).
pubmed: 24655063
doi: 10.1089/hum.2013.142
Nuijten, M. J. C., Wittenberg, W. & Lebmeier, M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: A UK analysis. Pharmacoeconomics 25, 55–71 (2007).
pubmed: 17192118
doi: 10.2165/00019053-200725010-00006
Beeler, J. A. & Coelingh, K. W. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: Effect of mutation upon fusion function. J. Virol. 63, 2941–2950 (1989).
pubmed: 2470922
pmcid: 250848
doi: 10.1128/jvi.63.7.2941-2950.1989
Johnson, S. et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215–1224 (1997).
pubmed: 9359721
doi: 10.1086/514115
Tayyari, F. et al. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat. Med. 17, 1132–1135 (2011).
pubmed: 21841784
doi: 10.1038/nm.2444
Collins, P. L., Huang, Y. T. & Wertz, G. W. Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. Proc. Natl. Acad. Sci. USA 81, 7683–7687 (1984).
pubmed: 6096849
doi: 10.1073/pnas.81.24.7683
pmcid: 392216
Battles, M. B. & McLellan, J. S. Respiratory syncytial virus entry and how to block it. Nat. Rev. Microbiol. 17, 233–245 (2019).
pubmed: 30723301
pmcid: 7096974
doi: 10.1038/s41579-019-0149-x
Huang, J., Diaz, D. & Mousa, J. J. Antibody epitopes of pneumovirus fusion proteins. Front. Immunol. 10, 2778 (2019).
pubmed: 31849961
pmcid: 6895023
doi: 10.3389/fimmu.2019.02778
McLellan, J. S., Yang, Y., Graham, B. S. & Kwong, P. D. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85, 7788–7796 (2011).
pubmed: 21613394
pmcid: 3147929
doi: 10.1128/JVI.00555-11
Swanson, K. A. et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc. Natl. Acad. Sci. USA 108, 9619–9624 (2011).
pubmed: 21586636
doi: 10.1073/pnas.1106536108
pmcid: 3111287
McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (80-). 340, 1113–1117 (2013).
doi: 10.1126/science.1234914
White, J. M., Delos, S. E., Brecher, M. & Schornberg, K. Structures and mechanisms of viral membrane fusion proteins: Multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol. 43, 189–219 (2008).
pubmed: 18568847
pmcid: 2649671
doi: 10.1080/10409230802058320
Samson, A. C., Willcocks, M. M., Routledge, E. G., Morgan, L. A. & Toms, G. L. A neutralizing monoclonal antibody to respiratory syncytial virus which binds to both F1 and F2 components of the fusion protein. J. Gen. Virol. 67(Pt 7), 1479–1483 (1986).
pubmed: 3755162
doi: 10.1099/0022-1317-67-7-1479
Johnson, P. R. & Collins, P. L. The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: Sequence conservation provides a structural basis for antigenic relatedness. J. Gen. Virol. 69, 2623–2628 (1988).
pubmed: 3171553
doi: 10.1099/0022-1317-69-10-2623
Walravens, K., Kettmann, R., Collard, A., Coppe, P. & Burny, A. Sequence comparison between the fusion protein of human and bovine respiratory syncytial viruses. J. Gen. Virol. 71, 3009–3014 (1990).
pubmed: 1703214
doi: 10.1099/0022-1317-71-12-3009
Schlender, J., Zimmer, G., Herrler, G. & Conzelmann, K.-K. Respiratory syncytial virus (RSV) fusion protein subunit F2, not attachment protein G, determines the specificity of RSV Infection. J. Virol. 77, 4609–4616 (2003).
pubmed: 12663767
pmcid: 152164
doi: 10.1128/JVI.77.8.4609-4616.2003
Bermingham, I. M., Chappell, K. J., Watterson, D. & Young, P. R. The heptad repeat C domain of the respiratory syncytial virus fusion protein plays a key role in membrane fusion. J. Virol. 92, JVI.01323-17 (2017).
doi: 10.1128/JVI.01323-17
Lopez, J. A. et al. Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein. J. Gen. Virol. 74, 2567–2577 (1993).
pubmed: 7506298
doi: 10.1099/0022-1317-74-12-2567
Sandritter, T. Palivizumab for respiratory syncytial virus prophylaxis. J. Pediatr. Heal. Care 13, 191–195 (1999).
doi: 10.1016/S0891-5245(99)90039-1
Zhao, X., Chen, F. P., Megaw, A. G. & Sullender, W. M. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J. Infect. Dis. 190, 1941–1946 (2004).
pubmed: 15529258
doi: 10.1086/425515
Schickli, J. H. et al. Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J. Clin. Invest. 125, 1637–1647 (2015).
pubmed: 25751145
pmcid: 4409022
doi: 10.1172/JCI78450
Jaberolansar, N. et al. Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein. Sci. Rep. 7, 11130 (2017).
pubmed: 28894111
pmcid: 5593926
doi: 10.1038/s41598-017-10415-w
Bukreyev, A. et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 82, 12191–12204 (2008).
pubmed: 18842713
pmcid: 2593351
doi: 10.1128/JVI.01604-08
Ngwuta, J. O. et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl. Med. 7, 309ra162 (2015).
pubmed: 26468324
pmcid: 4672383
doi: 10.1126/scitranslmed.aac4241
Polack, F. P. et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196, 859–865 (2002).
pubmed: 12235218
pmcid: 2194058
doi: 10.1084/jem.20020781
Habibi, M. S. et al. Impaired antibody-mediated protection and defective iga b-cell memory in experimental infection of adults with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 191, 1040–1049 (2015).
pubmed: 25730467
pmcid: 4435460
doi: 10.1164/rccm.201412-2256OC
Borochova, K. et al. Features of the human antibody response against the respiratory syncytial virus surface glycoprotein G. Vaccines 8, 1–21 (2020).
doi: 10.3390/vaccines8020337
Niespodziana, K. et al. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. FASEB J. 26, 1001–1008 (2012).
pubmed: 22121050
doi: 10.1096/fj.11-193557
Niespodziana, K. et al. PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze. Nat. Commun. 9, 2382 (2018).
pubmed: 29915220
pmcid: 6006174
doi: 10.1038/s41467-018-04591-0
Megremis, S. et al. Rhinovirus species-specific antibodies differentially reflect clinical outcomes in health and asthma. Am. J. Respir. Crit. Care Med. 198, 1490–1499 (2018).
pubmed: 30134114
pmcid: 7212800
doi: 10.1164/rccm.201803-0575OC
Niespodziana, K. et al. Toward personalization of asthma treatment according to trigger factors. J. Allergy Clin. Immunol. 145, 1529–1534 (2020).
pubmed: 32081759
doi: 10.1016/j.jaci.2020.02.001
Gallerano, D. et al. Comparison of the specificities of IgG, IgG-subclass, IgA and IgM reactivities in African and European HIV-infected individuals with an HIV-1 clade C proteome-based array. PLoS ONE 10, e0117204. https://doi.org/10.1371/journal.pone.0117204 (2015).
doi: 10.1371/journal.pone.0117204
pubmed: 25658330
pmcid: 4319756
Gallerano, D. et al. HIV microarray for the mapping and characterization of HIV-specific antibody responses. Lab Chip 15, 1574–1589 (2015).
pubmed: 25648429
doi: 10.1039/C4LC01510J
Curin, M. et al. Microarrayed dog, cat, and horse allergens show weak correlation between allergen-specific IgE and IgG responses. J. Allergy Clin. Immunol. 133, 918–921 (2014).
pubmed: 24406070
pmcid: 3969580
doi: 10.1016/j.jaci.2013.10.058
Dorofeeva, Y. et al. Past, presence, and future of allergen immunotherapy vaccines. Allergy Eur. J. Allergy Clin. Immunol. https://doi.org/10.1111/all.14300 (2020).
doi: 10.1111/all.14300
Zieglmayer, P. et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine 11, 43–57 (2016).
pubmed: 27650868
pmcid: 5049999
doi: 10.1016/j.ebiom.2016.08.022
Niederberger, V. et al. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. J. Allergy Clin. Immunol. 142, 497-509.e9 (2018).
pubmed: 29361332
pmcid: 6392176
doi: 10.1016/j.jaci.2017.09.052
Gallerano, D. et al. Biophysical characterization of recombinant HIV-1 subtype C virus infectivity factor. Amino Acids 40, 981–989 (2011).
pubmed: 20809132
doi: 10.1007/s00726-010-0725-x
Lou, X. et al. Unusual analyte-matrix adduct ions and mechanism of their formation in MALDI TOF MS of Benzene-1,3,5-tricarboxamide and urea compounds. J. Am. Soc. Mass Spectrom. 24, 1405–1412 (2013).
pubmed: 23812871
doi: 10.1007/s13361-013-0672-3
Matthews, J. M., Young, T. F., Tucker, S. P. & Mackay, J. P. The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil. J. Virol. 74, 5911–5920 (2000).
pubmed: 10846072
pmcid: 112087
doi: 10.1128/JVI.74.13.5911-5920.2000
Pahr, S. et al. Biochemical, biophysical and IgE-epitope characterization of the wheat food allergen, Tri a 37. PLoS ONE 9, e111483. https://doi.org/10.1371/journal.pone.0111483 (2014).
doi: 10.1371/journal.pone.0111483
pubmed: 25368998
pmcid: 4219751
Stern, D. A. et al. Exposure to a farming environment has allergen-specific protective effects on TH2-dependent isotype switching in response to common inhalants. J. Allergy Clin. Immunol. 119, 351–358 (2007).
pubmed: 17140649
doi: 10.1016/j.jaci.2006.10.013